HeatSYNC
Pre-clinical- Indications
- Uterine fibroids, Soft tissue ablation
Company intelligence / Profile preview
Theromics has developed proprietary injectable nanogels—HeatSYNC™ and CryoSYNC—that enhance the efficacy of soft tissue ablation procedures by improving energy transfer in tissues. Early studies suggest these gels can expand the treatment area, improve targeting, reduce recurrence rates, and enable localized drug delivery to minimize systemic side effects. The company has received NSF STTR grants and state innovation awards to advance its lead program toward FDA clearance. No published clinical trial results yet.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Theromics.